-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2021, what will be the results of in vitro diagnostic companies? According to data from Oriental Fortune Choice, as of April 24, 36 A-share in vitro diagnostic companies have disclosed their 2021 results (including forecasts)
.
Among them, nearly 80% of the in vitro diagnostic companies reported good performance, and 11 companies saw a year-on-year increase of more than 100%, including Jimin Medical, Rejing Bio, Xinkaiyuan, Jiu'an Medical, Mingde Bio, Wantai Bio, and Oriental Bio
.
Judging from the year-on-year growth rate of performance, Jimin Medical and Rejing Bio have both increased by more than 1000%
.
Among them, Jimin Medical is the big winner.
The company has benefited from a 22-fold increase in demand for testing and vaccine injections
.
According to the 2021 performance report released by the company on March 24, the company's operating income during the reporting period was 1.
1 billion yuan, a year-on-year increase of 26%; its net profit was 1.
47 billion yuan, a year-on-year increase of 2205.
39%
.
Rejing Bio is also not inferior.
Benefiting from the growth of overseas markets, Rejing Bio’s net profit in 2021 will increase by 18 times
.
According to the company's performance report, the revenue during the reporting period was 5.
372 billion yuan, a year-on-year increase of 946.
14%; the net profit attributable to owners of the parent company was 2.
193 billion yuan, a year-on-year increase of 1856.
81%
.
Also benefiting from the growth of overseas markets are Jiu'an Medical and Oriental Bio
.
Among them, Jiu'an Medical released its 2021 performance report on April 11, achieving revenue of 2.
5 billion yuan, a year-on-year increase of 25.
11%; net profit of 913 million yuan, a year-on-year increase of 276.
87%
.
The company also disclosed the performance forecast for the first quarter of 2022 on April 12, showing that in the first quarter, the company expects to achieve a net profit attributable to owners of the parent company of 14 billion yuan to 16 billion yuan, an increase of 36707.
43% to 41965.
63% over the same period last year.
.
According to the 2021 annual performance report of Oriental Bio, the company's net profit attributable to shareholders of the parent company in 2021 will be 4.
777 billion yuan, an increase of 184.
8% over the same period of the previous year.
.
In addition, the net profit growth of Xinkaiyuan, Xilong Science, and Mingde Bio in 2021 will all exceed 200%, and the net profit of Wantai Bio, Leadman, Kaipu Bio, and Yirui Technology will increase by more than 100%
.
On the whole, due to the expansion of market demand, the performance of in vitro diagnostic companies in 2021 is still relatively bright
.
It is worth mentioning that with the intensification of market competition and the advancement of local centralized procurement, the price of testing reagents has fallen, and more and more companies have begun to be affected
.
For example, companies such as BGI, Zhijiang Bio, and Novizan will all experience a decline in their performance in 2021.
The reason behind this is mainly due to the intensified market competition and the decline in the unit price of nucleic acid reagents and detection, resulting in a decline in the gross profit of the company's corresponding products
.
Jiu'an Medical also stated in the first quarter forecast of 2022 that due to the unpredictability of the development of the epidemic, the advancement of the vaccination plan, changes in market demand, and changes in the market competition environment, there is still certain uncertainty about whether future performance can continue to maintain rapid growth.
sex
.
Regarding the future development of the in vitro diagnostic industry, a number of brokerage research reports believe that the epidemic has stimulated the accelerated development of the IVD industry, and related companies have achieved explosive growth in performance.
The ability to multi-service offerings and transformative development
.
Since 2021, many companies, including Shengxiang Bio, Rejing Bio, and Oriental Bio, have been actively expanding their product lines and business scope through acquisitions, investments, etc.
, to inject more impetus into the company's subsequent sustainable growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, nearly 80% of the in vitro diagnostic companies reported good performance, and 11 companies saw a year-on-year increase of more than 100%, including Jimin Medical, Rejing Bio, Xinkaiyuan, Jiu'an Medical, Mingde Bio, Wantai Bio, and Oriental Bio
.
Judging from the year-on-year growth rate of performance, Jimin Medical and Rejing Bio have both increased by more than 1000%
.
Among them, Jimin Medical is the big winner.
The company has benefited from a 22-fold increase in demand for testing and vaccine injections
.
According to the 2021 performance report released by the company on March 24, the company's operating income during the reporting period was 1.
1 billion yuan, a year-on-year increase of 26%; its net profit was 1.
47 billion yuan, a year-on-year increase of 2205.
39%
.
Rejing Bio is also not inferior.
Benefiting from the growth of overseas markets, Rejing Bio’s net profit in 2021 will increase by 18 times
.
According to the company's performance report, the revenue during the reporting period was 5.
372 billion yuan, a year-on-year increase of 946.
14%; the net profit attributable to owners of the parent company was 2.
193 billion yuan, a year-on-year increase of 1856.
81%
.
Also benefiting from the growth of overseas markets are Jiu'an Medical and Oriental Bio
.
Among them, Jiu'an Medical released its 2021 performance report on April 11, achieving revenue of 2.
5 billion yuan, a year-on-year increase of 25.
11%; net profit of 913 million yuan, a year-on-year increase of 276.
87%
.
The company also disclosed the performance forecast for the first quarter of 2022 on April 12, showing that in the first quarter, the company expects to achieve a net profit attributable to owners of the parent company of 14 billion yuan to 16 billion yuan, an increase of 36707.
43% to 41965.
63% over the same period last year.
.
According to the 2021 annual performance report of Oriental Bio, the company's net profit attributable to shareholders of the parent company in 2021 will be 4.
777 billion yuan, an increase of 184.
8% over the same period of the previous year.
.
In addition, the net profit growth of Xinkaiyuan, Xilong Science, and Mingde Bio in 2021 will all exceed 200%, and the net profit of Wantai Bio, Leadman, Kaipu Bio, and Yirui Technology will increase by more than 100%
.
On the whole, due to the expansion of market demand, the performance of in vitro diagnostic companies in 2021 is still relatively bright
.
It is worth mentioning that with the intensification of market competition and the advancement of local centralized procurement, the price of testing reagents has fallen, and more and more companies have begun to be affected
.
For example, companies such as BGI, Zhijiang Bio, and Novizan will all experience a decline in their performance in 2021.
The reason behind this is mainly due to the intensified market competition and the decline in the unit price of nucleic acid reagents and detection, resulting in a decline in the gross profit of the company's corresponding products
.
Jiu'an Medical also stated in the first quarter forecast of 2022 that due to the unpredictability of the development of the epidemic, the advancement of the vaccination plan, changes in market demand, and changes in the market competition environment, there is still certain uncertainty about whether future performance can continue to maintain rapid growth.
sex
.
Regarding the future development of the in vitro diagnostic industry, a number of brokerage research reports believe that the epidemic has stimulated the accelerated development of the IVD industry, and related companies have achieved explosive growth in performance.
The ability to multi-service offerings and transformative development
.
Since 2021, many companies, including Shengxiang Bio, Rejing Bio, and Oriental Bio, have been actively expanding their product lines and business scope through acquisitions, investments, etc.
, to inject more impetus into the company's subsequent sustainable growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
